综合性多组学分析确定了对炎症性肠病的基因支持的可用药物标
Si-Chun Gu1, Si-Lu Zeng1, Wei Zhang1
1Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai 200032, China.
Journal, genetic engineering & biotechnology
|December 12, 2025
概括
这项研究确定了Thrombospondin-3 (THBS3),RORC和TNFRSF25作为炎症性肠病 (IBD) 的潜在药物标. 预测了候选药物,为IBD治疗提供了新的治疗途径.
科学领域:
- 遗传学和基因组学 遗传学和基因组学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),是一种慢性免疫介导的胃肠道疾病,其全球流行率正在上升.
- 目前对IBD的治疗方法有限,需要确定新的治疗点.
研究的目的:
- 系统地识别使用集成的多omics数据在IBD中具有潜在因果作用的可用药物基因.
- 为了利用遗传,转录和表观基因组数据集,在IBD中发现新的目标.
主要方法:
- 基于总结数据的门德尔随机化 (SMR) 和贝叶斯同位化被用来评估IBD的基因因果关系.
- 多omics分析集成了GWAS,甲基化和基因表达数据,在FinnGen队列中进行复制.
- 进行了全现象关联研究 (PheWAS),in silico药物重定位和分子对接模拟.
主要成果:
- 已确定Thrombospondin-3 (THBS3),RORC和TNFRSF25是IBD的潜在可用药物标.
- 这些基因在多个生物层和验证数据集中显示出与IBD的一致关联.
- 分子对接预测了几种候选药物,包括AM580和达沙替尼,它们与已识别的标具有很高的结合亲缘关系.
结论:
- 一种多层的奥米克方法为THBS3,RORC和TNFRSF25提供了基因支持的证据,作为IBD中可用药的标.
- 该研究确定了IBD治疗干预的有希望的候选药物.
- 需要进一步的临床验证,以开发基于这些新目标的有效IBD治疗方法.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
445
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
614
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
614
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
Inflammatory Bowel Disease II: Crohn's Disease
915
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
915
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
Inflammatory Bowel Disease I: Ulcerative Colitis
859
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
859


